铂类/培美曲塞方案治疗二代ALK抑制剂耐药后ALK阳性NSCLC的疗效
这项三中心回顾性研究评估了铂类/培美曲塞方案在二代ALK酪氨酸激酶抑制剂(TKI)耐药后晚期ALK阳性NSCLC中的疗效。58例入组患者中37例可评估疗效,确认客观缓解率为29.7%,全队列中位无进展生存期4.3个月;联合ALK TKI者无进展生存期长于单用化疗者。
要点
- 二代ALK TKI耐药后铂类/培美曲塞方案确认客观缓解率29.7%,中位缓解持续6.4个月
- 全队列中位无进展生存期4.3个月,联合ALK TKI者6.8个月优于单用化疗者3.2个月
- 结果提示继续ALK抑制可能增强化疗疗效
核心结论
- 铂类/培美曲塞方案在二代ALK TKI治疗失败后的ALK阳性NSCLC中显示出中等疗效。
- 与ALK TKI联合给药时活性可能更高,提示继续ALK抑制的潜在作用。
研究设计与样本
- 三中心回顾性研究。
- 入组条件为对一种或多种二代ALK TKI耐药且接受过铂类/培美曲塞方案的晚期ALK阳性NSCLC患者。
- 共58例患者符合条件,其中37例基线有可测量病灶且扫描可评估疗效。
主要发现
- 铂类/培美曲塞方案的确认客观缓解率为29.7%(11/37例;95%CI 15.9%-47.0%)。
- 中位缓解持续时间为6.4个月(95%CI 1.6个月-未达到)。
- 全队列中位无进展生存期为4.3个月(95%CI 2.9-5.8个月)。
- 联合ALK TKI组与单用铂类/培美曲塞组的中位无进展生存期分别为6.8个月与3.2个月(风险比=0.33;p=0.025)。
临床怎么用
- 二代ALK TKI耐药后可考虑铂类/培美曲塞方案,但疗效有限,需权衡获益。
- 联合ALK TKI可能改善无进展生存期,支持继续ALK抑制的策略。
局限性
- 回顾性研究设计。
- 仅37例可评估疗效,样本量有限。
- 来自三个机构,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The current standard initial therapy for advanced ALK receptor tyrosine kinase (ALK)-positive NSCLC is a second-generation ALK tyrosine kinase inhibitor (TKI) such as alectinib. The optimal next-line therapy after failure of a second-generation ALK TKI remains to be established; however, standard options include the third-generation ALK TKI lorlatinib or platinum/pemetrexed-based chemotherapy. The efficacy of platinum/pemetrexed-based chemotherapy has not been evaluated in cases that are refractory to second-generation TKIs. METHODS: This was a retrospective study performed at three institutions. Patients were eligible if they had advanced ALK-positive NSCLC refractory to one or more second-generation ALK TKI(s) and had received platinum/pemetrexed-based chemotherapy. RESULTS: Among 58 patients eligible for this study, 37 had scans evaluable for response with measurable disease at baseline. The confirmed objective response rate to platinum/pemetrexed-based chemotherapy was 29.7% (11 of 37 patients; 95% confidence interval [CI]: 15.9% - 47.0%), with median duration of response of 6.4 months (95% CI: 1.6 months - not reached). The median progression-free survival for the entire cohort was 4.3 months (95% CI: 2.9 - 5.8 months). Progression-free survival was longer in patients who received platinum/pemetrexed in combination with an ALK TKI compared to those who received platinum/pemetrexed alone (6.8 months vs. 3.2 months, respectively; hazard ratio = 0.33; p = 0.025). CONCLUSIONS: Platinum/pemetrexed-based chemotherapy shows modest efficacy in ALK-positive NSCLC after failure of second-generation ALK TKIs. The activity may be higher if administered with an ALK TKI, suggesting a potential role for continued ALK inhibition.
引用
- Lin JJ, Schoenfeld AJ, Zhu VW, et al. Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. J Thorac Oncol. 2019. PMID: 31669591. doi:10.1016/j.jtho.2019.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。